Early interim data from phase 2 clinical studies demonstrate encouraging clinical activity in r/m HNSCC that is substantially superior to historical results for standard approved therapies and may reflect a more effective treatment of the stem-cell-like LGR5+ cells within the cancer. Here, LGR5 is linked to cancer.